

3. (Amended) Vector according to Claim 1, characterized in that the nucleic acid sequence codes for the surface marker is the sequence indicated in SEQ ID NO: 1, 3 or 5 or for a fragment, a mutant or variant of the same.

A1  
B1  
4. (Amended) Vector according to Claim 1, characterized in that it is a retroviral vector.

5. (Amended) Vector according to Claim 1, characterized in that it contains a nucleic acid sequence coding for a further surface marker.

A2  
B1  
9. (Amended) Host cell, characterized in that it is transduced with a vector according to Claim 1.

A3  
12. (Amended) Method for the detection of genetically modified cells, characterized in that the cells are transduced with a vector according to Claim 1 and the transduced cells are identified by detection of the surface marker.

13. (Amended) Method for the selection of genetically modified cells, characterized in that the cells are transduced with a vector according to Claim 1, bound to an agent specific to the surface marker, and separated from the genetically unmodified cells.

A4  
16. (Amended) Method according to Claim 14, characterized in that the nucleic acid sequence codes for a surface marker according to SEQ ID NO: 2, 4 or 6 or for a fragment or a variant of the same.

17. (Amended) Method according to Claims 14, characterized in that the nucleic acid sequence coding for the surface marker is the sequence indicated in SEQ ID NO: 1, 3 or 5 or a fragment, mutant or variant of the same.

18. (Amended) Method according to Claim 14, characterized in that the vector is a retroviral vector.

19. (Amended) Method according to Claim 14, characterized in that the vector corresponding to DSM 13396 is used.

**ZANDER**

Serial No. **Unknown**

a5  
20. (Amended) Method according to Claim 12, characterized in that the cells are human cells.

a5  
22. (Amended) Kit containing a vector according to Claim 1 and means for the specific detection of a surface marker, and further agents and aids required for carrying out a detection.

23. (Amended) Kit containing a vector of Claim 14 and, means for the specific detection of a surface marker and further agents and aids required for carrying out a detection.

a6  
26. (Amended) Use of a vector according to Claim 1 for *in vitro* transduction of T-lymphocytes.

27. (Amended) Use of a vector according to Claim 1 for gene therapeutic treatment.

28. (Amended) Use of T-lymphocytes which are transduced with a vector according to Claim 1, for gene therapeutic treatment.

31. (Amended) Gene therapeutic drug, containing a vector according to Claim 1.

a7  
32. (Amended) Gene therapeutic drug, containing T-lymphocytes, which are transduced with a vector according to Claim 1.

**REMARKS**

An inventor's Declaration is attached.

The above amendments of the claims have been made to reduce multiple dependencies and claims filing fees. The amendments have been made without prejudice.

The specification has been amended to include the attached Sequence Listing. The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added. A separate Letter to this effect is attached.

Also attached is a copy of the Deposit receipt and viability statement for Deposit Accession No. DSM 13396, which was received by DSMZ-Deutsche Sammlung Von